Investigational Waldenström’s Macroglobulinemia Treatment Earns Orphan Drug Designation
source: pixabay.com

Investigational Waldenström’s Macroglobulinemia Treatment Earns Orphan Drug Designation

According to a story from BioSpace, the biotechnology company Ascentage Pharma has just announced that it has been given Orphan Drug designation from the US Food and Drug Administration (FDA).…

Continue Reading Investigational Waldenström’s Macroglobulinemia Treatment Earns Orphan Drug Designation
The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
source: pixabay.com

The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

  Orphan drug designations are granted by the FDA to drugs and biologics that are developed for the treatment of rare diseases.  According to a recent article in Biospace, Oncternal…

Continue Reading The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
Recruitment for South Korea’s Rare Disease National Bio Big Data Project Begins
source: pixabay.com

Recruitment for South Korea’s Rare Disease National Bio Big Data Project Begins

According to a story from Korea Biomedical Review, Seoul National University Hospital (SNUH) in South Korea has just announced recently that the process of recruiting patients for the National Bio…

Continue Reading Recruitment for South Korea’s Rare Disease National Bio Big Data Project Begins
New Treatment Recommended for Refractory MAC Lung Disease
source: pixabay.com

New Treatment Recommended for Refractory MAC Lung Disease

According to a story from PR Newswire, new international treatment recommendation guidelines have recently been updated for nontuberculous mycobacterial (NTM) lung disease. The update pertains to a variant known as Mycobacterium…

Continue Reading New Treatment Recommended for Refractory MAC Lung Disease
Rare Pediatric Disease Designation Awarded to Investigative Therapy for POMC and LEPR Deficiency Obesities
source: pixabay.com

Rare Pediatric Disease Designation Awarded to Investigative Therapy for POMC and LEPR Deficiency Obesities

Rare pediatric disease designation has just been granted to Rhythm Pharmaceuticals for their investigative therapy called setmelanotide. This drug is being investigated as a therapeutic option for two conditions- leptin…

Continue Reading Rare Pediatric Disease Designation Awarded to Investigative Therapy for POMC and LEPR Deficiency Obesities
Familial Chylomicronemia Syndrome Foundation Announces Support for HEART Act
https://pixabay.com/en/book-book-gift-heart-gift-read-1760998/

Familial Chylomicronemia Syndrome Foundation Announces Support for HEART Act

  In a July 9 press release, the Familial Chylomicronemia Syndrome (FCS) Foundation announced its support for a bill introduced by Congressman Paul Tonko (D-NY) and David B. McKinley (R-WV).…

Continue Reading Familial Chylomicronemia Syndrome Foundation Announces Support for HEART Act
FDA Approves PRRT to Treat Neuroendocrine Tumors
source: pixabay.com

FDA Approves PRRT to Treat Neuroendocrine Tumors

  Patients with inoperable or metastasized neuroendocrine tumors (NETs) may now benefit from recently FDA approved peptide receptor radionuclide therapy (PRRT) according to a recent article in MedPage Today. The…

Continue Reading FDA Approves PRRT to Treat Neuroendocrine Tumors
Myelodysplastic Syndromes: Phase 1 Trial Results Find Potential in New Combination Therapy
source: pixabay.com

Myelodysplastic Syndromes: Phase 1 Trial Results Find Potential in New Combination Therapy

According to a story from GlobeNewswire, the biopharmaceutical company Onconova Therapeutics, Inc. has recently published results from a phase 1 clinical trial that was sponsored by the company. This trial…

Continue Reading Myelodysplastic Syndromes: Phase 1 Trial Results Find Potential in New Combination Therapy